01 Increasing Outsourcing Services by Pharmaceutical CompaniesRapid technological advancements (such as automation and artificial intelligence), the need for CROs, CMOs, and CDMOs, and rising research investments are all impacting the healthcare market as it is undergoing a process of dynamic change. Many pharmaceutical companies find that outsourcing activities help them increase operational effectiveness, broaden their geographic reach, cut resource costs, acquire therapeutic expertise, and enhance on-demand services. Small and midsize biopharmaceutical companies account for about 75% of the pipelines for new drugs. Due to their high-profit margins, these businesses are easy targets for healthcare providers looking to cut costs. Therefore, it is profitable for these businesses to outsource services to third-party organizations with the necessary expertise and equipment rather than invest in building their infrastructure. Many pharmaceutical companies are looking for opportunities in the advanced supply chain to optimize the development of their molecule.
02 Increasing Demand for One-Stop-Shop CdmosInnovation and speed in the clinic are essential to many pharmaceutical companies. In the one-stop-shop service model, a CRO handles everything from the active pharmaceutical ingredient (API) to the dosage form and from early development to commercialization. To offer these services, a CDMO needs to have a wide range of enabling technologies and the ability to handle specific problem statements. Outsourcing Pharma states that sponsors do not just drive the one-stop-shop service. Instead, it is a way for CMOs to compete in the fragmented healthcare contract pharma manufacturing space by offering M&A at lower costs. Many CROs are becoming one-stop shops (full-service providers) offering a long list of R&D services, both core, and auxiliary R&D services. As pharmaceutical and biopharmaceutical companies try to become more competitive, working with a CRO that offers benefits from start to finish can be smart. As a result, there is a growing demand for one-stop-shop services from CROs and pharmaceutical companies.
01 Compliance Issues While OutsourcingOutsourcing is much faster than licensing since negotiating a license takes longer. However, a CRO may be working on multiple projects for different clients simultaneously, which can cause delays and limits on production capacity. Also, when a company outsources, it loses control over its operations, making communication and decision-making less effective. Compliance issues that need to be assessed include data privacy, import/export laws, immigration issues, property rights, local law concerns, enforcement, and the ability to move or let someone go. A client must share the same primary IP address. The central part is the core IP, which can lead to problems with infringement. When drafting contracts, clients must keep transparency in mind. With technologies facilitated by digitization and artificial intelligence, it is possible to overcome these obstacles.
01 Rising Incidence of Cardiovascular DiseasesHeart and blood vessel diseases are the primary cause of death worldwide. Cardiovascular diseases will likely worsen as the elderly population grows. It is essential to detect cardiovascular disease as soon as possible to begin treatment with counseling and medication. Health policies that make it easy and affordable for people to make healthy choices are essential for getting people to start and keep healthy habits.In addition, hypertension, diabetes, and high blood lipids must be treated with drugs in order to reduce cardiovascular risk and control heart attacks and strokes in people with these conditions. The increase in outsourcing of cardiovascular devices is attributable to the rising demand for these devices due to the increasing incidence of associated diseases. Also, cardiovascular devices are more likely to be outsourced because they are hard to make and need a lot of technical knowledge.
March 2026 Lonza expanded its healthcare CDMO capabilities through investments in advanced manufacturing infrastructure supporting biologics, cell and gene therapies, and pharmaceutical development services.
January 2026 Catalent expanded its pharmaceutical development and manufacturing capabilities with enhanced biologics, clinical supply, and drug delivery services for global healthcare companies.
November 2025 Samsung Biologics expanded its biologics manufacturing capacity through facility investments and technology enhancements, strengthening its position as a global healthcare CDMO provider.
September 2025 Thermo Fisher Scientific (Patheon) expanded its contract development and manufacturing capabilities with new biologics and pharmaceutical production solutions.